Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch. Health Study Area: NASH

Please Log In/Join Now first, and then use this function!

Screening has been met.
deactivate all countries


A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection - CA209-8FC

Updated: 6 August, 2020   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1/Phase 2


  • Gender(s)

  • 18+

    Age Range

  • 31


  • Recruiting

Treatment Options

Study Arms
Experimental: Arm A (Process C)
Drug: Nivolumab
Experimental: Arm B (Process D)
Drug: Nivolumab

Key Eligibility Criteria

Inclusion Criteria: - Late Stage melanoma that is completely surgically resected and pathologically absent - Participants must not have received anti-cancer therapy greater than equal to (>=) 6 months prior to randomization - Imaging studies to include Computed tomography (CT), Magnetic resonance imaging (MRI), positron emission tomography (PET) scans that show no clinically detectable nodes on imaging Exclusion Criteria: - Participants must not have a history of ocular/uveal melanoma - Participants with active, known, or suspected autoimmune disease(s) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll - Participants must not have prior malignancy active within the previous 3 years except for locally curable cancers - Participants must not have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration. - Participants must not have had prior therapy for melanoma except surgery, for the melanoma lesion(s) adjuvant radiation therapy after neurosurgical resection for CNS lesions and except for participants who received prior adjuvant interferon therapy - Treatment directed against the resected melanoma that is administered after complete resection other than adjuvant radiation

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com